Subcision Versus Subcision With Suction for the Treatment of Atrophic Acne Scars: A Randomized, Split-Face Clinical Trial.

Dermatol SurgApr 23, 2026 (epub)
Clinical ResearchDermatology

Sdrah Diab, Ibrahim Diab, Jamal Khaddam

✦ AI-curated · Sources linked

In 30 seconds

This randomized, split-face clinical trial evaluated the effectiveness of subcision alone versus subcision with suction in 27 patients with atrophic acne scars. Both treatments significantly improved scar appearance, but subjective assessments indicated that suction-assisted subcision was superior, with physician and patient ratings showing significant differences (p = .002 and p = .026, respectively).

Key findings

  • Both treatment methods led to significant improvement in scar measures over time (p < .05).
  • No significant differences were found in objective outcomes between the two sides.
  • Suction-assisted subcision resulted in higher physician-rated scores (p = .002).
  • Patient-rated scores for suction-assisted subcision were also significantly higher (p = .026).

Why it matters

Understanding the comparative effectiveness of treatment options for atrophic acne scars is crucial for optimizing patient outcomes. This study highlights the potential benefits of adjunctive suction in enhancing subjective perceptions of scar improvement.

Source

PubMed · PMID 42054473

Published in Dermatol Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Dermatology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.